

Dilemmas in Clinical Cardiology

Dilemmas in Clinical Cardiology

Melvin D. Cheitlin, M.D. / Editor

Professor of Medicine
University of California, San Francisco
Associate Chief of Cardiology
San Francisco General Hospital
San Francisco, California

CARDIOVASCULAR CLINICS
Albert N. Brest, M.D. / Editor-in-Chief

James C. Wilson Professor of Medicine
Director, Division of Cardiology
Jefferson Medical College
Philadelphia, Pennsylvania



F. A. DAVIS COMPANY • Philadelphia

Copyright © 1990 by F. A. Davis Company

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Printed in the United States of America

Last digit indicates print number: 10 9 8 7 6 5 4 3 2 1

Printed on acid-free paper effective with Volume 17, Number 1.

NOTE: As new scientific information becomes available through basic and clinical research, recommended treatments and drug therapies undergo changes. The author(s) and publisher have done everything possible to make this book accurate, up-to-date, and in accord with accepted standards at the time of publication. However, the reader is advised always to check product information (package inserts) for changes and new information regarding dose and contraindications before administering any drug. Caution is especially urged when using new or infrequently ordered drugs.

Library of Congress Cataloging in Publication Data

Cardiovascular clinics. 21/1

Philadelphia, F. A. Davis, 1969-

v. ill. 27 cm.

Editor: v. 1- A. N. Brest

Key title: Cardiovascular clinics, ISSN 0069-0384.

1. Cardiovascular system—Diseases—Collected works. I.

Brest, Albert N., ed.

[DNLM: W1 CA77N]

RC681.A1C27 616.1

ISBN 0-8036-1712-7

70-6558

MARC-S

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by F. A. Davis Company for users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the fee of \$.10 per copy is paid directly to CCC, 27 Congress St., Salem, MA 01970. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is: 8036-8477/89 0 + \$.10.

Contributors

Mark W. Anderson, M.D.

Professor of Radiology

University of California, San Francisco Medical Center

San Francisco, California

Michael A. Azrin, M.D.

Cardiology Division

Yale University School of Medicine

New Haven, Connecticut

Kanu Chatterjee, M.B., F.R.C.P.

Lucie Stern Professor of Medicine

Associate Chief, Division of Cardiology

University of California, San Francisco

San Francisco, California

Melvin D. Cheitlin, M.D.

Professor of Medicine

University of California, San Francisco

Associate Chief of Cardiology

San Francisco General Hospital

San Francisco, California

Richard B. Devereux, M.D.

Associate Professor of Medicine

Cornell University Medical College

Director, Echocardiography Laboratory

The New York Hospital

New York, New York

Laurence M. Epstein, M.D.

*Clinical Cardiac Electrophysiology and Cardiovascular Research
University of California, San Francisco
San Francisco, California*

Annmarie Errichetti, M.D.

*Assistant Professor of Medicine
University of Massachusetts Medical School
Director of Cardiac Noninvasive Laboratory
The Medical Center of Central Massachusetts/Memorial
Worcester, Massachusetts*

Michael D. Ezekowitz, M.D., Ph.D.

*Associate Professor of Medicine (Cardiology)
Yale University School of Medicine
New Haven, Connecticut*

Valentin Fuster, M.D.

*Arthur M. and Hilda A. Master Professor of Medicine
Chief, Division of Cardiology
Mt. Sinai Medical Center
New York, New York*

William H. Gaasch, M.D.

*Professor of Medicine
University of Massachusetts Medical School
Chief, Cardiology Section
The Medical Center of Central Massachusetts/Memorial
Worcester, Massachusetts*

Barry H. Greenberg, M.D.

*Professor of Medicine
Division of Cardiology
Oregon Health Sciences University
Portland, Oregon*

Joshua M. Greenberg, M.D.

*Assistant Professor of Medicine
University of Massachusetts Medical School
Director, Cardiac Catheterization Laboratory
The Medical Center of Central Massachusetts/Memorial
Worcester, Massachusetts*

Rolf M. Gunnar, M.D., F.A.C.P., F.R.C.P.

*John W. Clarke Professor of Medicine
Chairman, Department of Medicine
Loyola University School of Medicine
Maywood, Illinois*

Jonathan L. Halperin, M.D.
Associate Professor of Medicine
Division of Cardiology
Mount Sinai Medical Center
New York, New York

Charles B. Higgins, M.D.
Professor of Radiology
Chief, Magnetic Resonance Imaging
University of California, San Francisco Medical Center
San Francisco, California

Russell J. Ivanhoe, M.D.
Attending Cardiologist
Florida Hospital
Orlando, Florida

Spencer B. King III, M.D.
Professor of Medicine (Cardiology) and Radiology
Director, Andreas Gruentzig Cardiovascular Center
Emory University School of Medicine
Atlanta, Georgia

Paul Kligfield, M.D.
Associate Professor of Medicine
Director, Cardiac Graphics Laboratory
Cornell University Medical College
The New York Hospital
New York, New York

Daniel L. Kulick, M.D.
Assistant Professor of Medicine
Director, Cardiac Catheterization Laboratory
University of Southern California School of Medicine
Los Angeles, California

Herbert J. Levine, M.D.
Professor of Medicine
Cardiology Section
Tufts University School of Medicine
Senior Physician
New England Medical Center
Boston, Massachusetts

Howard S. Lewis, M.D.
Division of Cardiology
Oregon Health Sciences University
Portland, Oregon

Barry M. Massie, M.D.

Professor of Medicine

University of California, San Francisco

Director, Coronary Care Unit and Hypertension Unit

Veterans Administration Medical Center

San Francisco, California

Charles R. McKay, M.D.

Associate Professor of Medicine

Department of Internal Medicine

Division of Cardiovascular Disease

University of Iowa College of Medicine

Iowa City, Iowa

Khether E. Raby, M.D.

Department of Medicine

Cardiovascular Division

Brigham and Women's Hospital

Boston, Massachusetts

Shahbudin H. Rahimtoola, M.B., F.R.C.P.

George C. Griffith Professor of Cardiology

Professor of Medicine

Chief, Section of Cardiology

University of Southern California School of Medicine

Los Angeles, California

Stuart Rich, M.D.

Associate Professor of Medicine

Chief, Division of Cardiology

University of Illinois at Chicago

Chicago, Illinois

Melvin M. Scheinman, M.D.

Professor of Medicine

Chairman, Clinical Cardiac Electrophysiology Section

University of California, San Francisco

San Francisco, California

Andrew P. Selwyn, M.D.

Associate Professor of Medicine

Harvard Medical School

Director, Cardiac Catheterization Laboratory

Brigham and Women's Hospital

Boston, Massachusetts

James P. Srebro, M.D.

Assistant Professor of Medicine

Division of Cardiology

University of California, San Francisco

San Francisco, California

Peter Stecy, M.D.

Assistant Professor of Medicine

Loyola University School of Medicine

Maywood, Illinois

Bernardo Stein, M.D.

Division of Cardiology

Mount Sinai Medical Center

New York, New York

Eric J. Topol, M.D.

Associate Professor of Internal Medicine

Director, Cardiac Catheterization Laboratories

University of Michigan Medical Center

Ann Arbor, Michigan

Contents

Part I

CORONARY HEART DISEASE	1
1 Is Noninvasive Risk Stratification Sufficient, or Should All Patients Undergo Cardiac Catheterization and Angiography after a Myocardial Infarction?	3
<i>Daniel L. Kulick, M.D., and Shahbudin H. Rahimtoola, M.B., F.R.C.P.</i>	
Definition of the Problem	3
Information Learned from Cardiac Catheterization and Angiography	4
Limitations of Noninvasive Testing Following Myocardial Infarction	9
Expectations of Noninvasive Risk Stratification	12
Special Considerations	14
Non-Q Wave Myocardial Infarction	14
"Young" Patients	14
"Older" Patients	15
Patients Receiving Thrombolytic Treatment	15
Inferior Myocardial Infarction	16
Hibernating and Stunned Myocardium	16
Cost Analysis	16
Commentary—Melvin D. Cheitlin, M.D.	26
2 Should the Asymptomatic Patient with a Significant Proximal LAD Stenosis Undergo PTCA?	31
<i>Kanu Chatterjee, M.B., F.R.C.P., and James P. Srebro, M.D.</i>	
Prognosis of Left Anterior Descending Coronary Artery (LAD) Stenosis	32
Therapy and Prognosis	34
Suggested Management Approach	38
Commentary—Melvin D. Cheitlin, M.D.	42
3 How Should We Manage Continuing Asymptomatic Ischemia in Patients Treated for Angina Pectoris?	45
<i>Khether E. Raby, M.D., and Andrew P. Selwyn, M.D.</i>	
Asymptomatic Ischemia in a Population at Risk	46

Detection of Asymptomatic Ischemia: Correlation with Anatomy and Prognosis	47
Myocardial Ischemia During Daily Life	48
Treatment of Asymptomatic Ischemia: Does Revascularization Work?	50
Commentary—Melvin D. Cheitlin, M.D.	58
 4 How Should Intravenous Thrombolytic Agents for Acute Myocardial Infarction Be Selected?	57
Eric J. Topol, M.D.	
Historical Perspective	57
The Ideal Agent	58
Profiles of Thrombolytic Agents	60
Streptokinase	60
Tissue Plasminogen Activator	63
APSAC	66
Urokinase	67
Prourokinase	67
Comparative Features	68
Commentary—Melvin D. Cheitlin, M.D.	76
 Should Asymptomatic Patients with Coronary Artery Disease and Nonsustained Ventricular Tachycardia Be Treated with Antiarrhythmic Drugs?	79
Laurence M. Epstein, M.D., and Melvin M. Scheinman, M.D.	
What Is Nonsustained Ventricular Tachycardia?	80
Are Asymptomatic Patients with Coronary Artery Disease and Nonsustained Ventricular Tachycardia at Increased Risk?	80
Determination of Risk Factors	84
Noninvasive Techniques	84
Continuous Ambulatory Monitoring	84
Evaluation of Cardiac Function	85
Signal-Averaged Late Potentials	85
Invasive Techniques	87
Electrophysiologic Testing (Programmed Stimulation)	87
Predictors and Incidence of a Positive Test	88
Risk of Inducible Ventricular Tachycardia	90
Overall Risk	91
Treatment	91
Treatment Options	91
Treatment Selection	92
Commentary—Melvin D. Cheitlin, M.D.	102
 6 Should Patients with Large Anterior Wall Myocardial Infarction Have Echocardiography to Identify Left Ventricular Thrombus and Should They Be Anticoagulated?	105

Michael D. Ezekowitz, M.D., Ph.D., and Michael A. Azrin, M.D.

Techniques for Diagnosis of Left Ventricular Thrombi	105
Echocardiography	105
Accuracy of Echocardiography	106
The Optimal Timing for Imaging	107
When Do Systemic Emboli Occur Following Acute Myocardial Infarction?	108
Stratification of Risks	108
Competing Technology	110
Platelet Imaging	110
Magnetic Resonance Imaging/X-Ray Computed Tomography	111
Contrast Ventriculography	112
Treatment	112
Anticoagulation	112
Thrombolytic Therapy	114
Thrombectomy/Aneurysmectomy/Infarctectomy	116
Antiplatelet Drugs	116
Commentary—Melvin D. Cheitlin, M.D.	121
7 Has Multivessel Angioplasty Displaced Surgical Revascularization?	123
<i>Spencer B. King III, M.D., and Russell J. Ivanhoe, M.D.</i>	
Percutaneous Transluminal Coronary Angioplasty (PTCA)	124
Early Results	124
Complications	124
Surgical Backup	125
AHA/ACC Guidelines	125
Restenosis	126
PTCA in Multivessel Coronary Artery Disease	127
Extent of Revascularization	128
Trends in Surgery	131
Effect of PTCA on Referral Patterns to Surgery	132
Costs: PTCA versus CABG	132
Present Indications for Mode of Revascularization	132
Randomized Trials	133
Commentary—Melvin D. Cheitlin, M.D.	138

Part 2

VALVULAR HEART DISEASE 141

8 Is the Mitral Valve Prolapse Patient at High Risk of Sudden Death Identifiable?	143
<i>Paul Kligfield, M.D., and Richard B. Devereux, M.D.</i>	
What Evidence Suggests that Sudden Death and Malignant Arrhythmias Are Features of Mitral Valve Prolapse?	144
What Risk Factors for Sudden Death Have Been Suggested in Mitral Valve Prolapse?	145
What Is the Prevalence of Arrhythmias in Mitral Valve Prolapse?	146

How Often Can Sudden Death Be Attributed to Mitral Valve Prolapse in Unselected Populations?	148
What Is the Risk of Sudden Death in Unselected Populations of Mitral Valve Prolapse Patients Without Important Mitral Regurgitation?	148
Implications of Treatment of Complex Arrhythmias in Patients with Mitral Valve Prolapse Who Do Not Have Important Mitral Regurgitation	149
What Is the Risk of Sudden Death in Mitral Valve Prolapse Patients with Important Mitral Regurgitation?	150
Are Complex Arrhythmias in Mitral Prolapse More Prevalent When Severe Mitral Regurgitation Is Present?	151
How Do Arrhythmia Complexity and Ventricular Function Relate to Mortality in Mitral Regurgitation?	153
Sudden Death and Arrhythmias in Mitral Valve Prolapse: An Overview	154
Commentary—Melvin D. Cheitlin, M.D.	158
 9 Is Valve Surgery Indicated in Patients with Severe Mitral Regurgitation Even If They Are Asymptomatic?	161
<i>Herbert J. Levine, M.D.</i>	
The Natural History of Patients with Severe Asymptomatic Mitral Regurgitation	162
The Early and Late Risks of Surgery in Asymptomatic Patients with Chronic Mitral Regurgitation	163
The Role of Ventricular Function in the Natural History of Chronic Mitral Regurgitation	165
Assessment of Ventricular Function in Mitral Regurgitation ...	166
The Asymptomatic Patient with Severe Mitral Regurgitation ...	166
Indications for Surgery in Asymptomatic Mitral Regurgitation ...	167
Commentary—Melvin D. Cheitlin, M.D.	171
 10 Should Patients with Mitral Stenosis Who Are Acceptable Surgical Commissurotomy Candidates Now Have Balloon Valvuloplasty Treatment?	175
<i>Charles R. McKay, M.D.</i>	
Natural History and Morphology of Rheumatic Mitral Stenosis	176
Results of Transatrial Closed Mitral Commissurotomy	177
Results of Transventricular Closed Mitral Commissurotomy ...	180
Results of Open Mitral Commissurotomy	183
Current Techniques of Mitral Balloon Valvuloplasty	185
Immediate Results of Mitral Balloon Valvuloplasty	185
Morphologic Studies: Mechanism of Improved Mitral Valve Function	187
Improved Exercise Capacity and Exercise Hemodynamics ...	189
Mid-Term Follow-up Studies	190
Patient Selection for Mitral Balloon Valvuloplasty	190
Commentary—Melvin D. Cheitlin, M.D.	196

11	Is Valve Replacement Indicated in Asymptomatic Patients with Aortic Stenosis or Aortic Regurgitation?	199
	<i>Annmarie Errichetti, M.D., Joshua M. Greenberg, M.D., and William H. Gaasch, M.D.</i>	
	Aortic Stenosis	199
	Symptomatic Patients	201
	Asymptomatic Patients	201
	Sudden Death	202
	Surgical Risk	202
	Complications of Prosthetic Valves	202
	High-Risk Patients	203
	Aortic Regurgitation	203
	Symptomatic Patients	205
	Asymptomatic Patients	205
	Normal Left Ventricular Function	206
	Abnormal Left Ventricular Function	206
	Commentary—Melvin D. Cheitlin, M.D.	211
12	Does the Patient with Infective Endocarditis and a Large Vegetation on the Mitral or Aortic Valve Need Surgery?	215
	<i>Howard S. Lewis, M.D., and Barry H. Greenberg, M.D.</i>	
	Definition	216
	Diagnosis	217
	Incidence	218
	Epidemiology	219
	Clinical Manifestations	220
	Treatment	222
	Commentary—Melvin D. Cheitlin, M.D.	227
Part 3		
	OTHER CARDIOVASCULAR CHALLENGES	229
13	Should Patients with Atrial Fibrillation Be Anticoagulated Prior to and Chronically Following Cardioversion?	231
	<i>Bernardo Stein, M.D., Jonathan L. Halperin, M.D., and Valentin Fuster, M.D.</i>	
	Pathophysiology of Embolism in Atrial Fibrillation	232
	Relation of Etiology to Embolic Risk in Atrial Fibrillation	233
	Valvular Heart Disease	233
	Nonvalvular Heart Disease	234
	Coronary Artery Disease	234
	Cardiomyopathy	235
	Hypertension	235
	Thyrotoxicosis	235
	Lone Atrial Fibrillation	236
	Stratification of Embolic Risk	236
	High Risk	236
	Medium-High Risk	238

Medium-Low Risk	238
Low Risk	239
Risk of Embolism in Relation to Cardioversion	239
Recommendations for Anticoagulation Prior to and after	
Cardioversion	243
Prophylactic Anticoagulation for Cardioversion	243
Long-term Anticoagulation	244
Commentary—Melvin D. Cheitlin, M.D.	248
14 Should All Patients with Congestive Heart Failure and Dilated Cardiomyopathy Be Treated with Vasodilators?	251
<i>Barry M. Massie, M.D.</i>	
Background	251
Question 1: Should Patients with Refractory or Severe Symptoms of CHF Receive Vasodilators?	253
Question 2: Should Patients with Mild and Moderate CHF Receive Vasodilators?	253
Question 3: Should Patients with Dilated Cardiomyopathy with Few or No Symptoms Receive Vasodilators?	256
Question 4: When Should Vasodilators Be Initiated in Relation to Other Therapeutic Agents, Such as Diuretics and Digoxin?	258
Question 5: Should a Distinction Be Made between Direct Vasodilators and ACE Inhibitors?	260
Commentary—Melvin D. Cheitlin, M.D.	263
15 Should Patients with Pulmonary Hypertension and Increased Pulmonary Resistance Be Treated with Vasodilators?	265
<i>Stuart Rich, M.D.</i>	
The Action of Vasodilators on the Pulmonary Vascular Bed in Pulmonary Hypertension	265
Defining Beneficial Effects from Vasodilators in Pulmonary Hypertension	267
Defining Adverse Effects of Vasodilators in Pulmonary Hypertension	268
Documentation of Clinical Benefits of Vasodilators in Pulmonary Hypertension	269
Primary Pulmonary Hypertension	269
Secondary Pulmonary Hypertension	271
Commentary—Melvin D. Cheitlin, M.D.	275
16 Is Intermittent Dobutamine Infusion Useful in the Treatment of Patients with Refractory Congestive Heart Failure?	277
<i>Peter Stecy, M.D., and Rolf M. Gunnar, M.D., F.A.C.P., F.R.C.P.</i>	
Pharmacology and Clinical Profile of Dobutamine	278
Basic Pharmacology	278
Clinical Effects	278
Tolerance to Dobutamine	279

Evidence of Prolonged Benefit	279
Uncontrolled Studies	279
A Randomized, Controlled Trial	280
Mechanisms for Sustained Effects	280
Myocardial Effects	280
Conditioning Effects	281
Trials of Unmonitored, Ambulatory Therapy	282
Intermittent, Monitored Infusions	283
Ohio State University Experience	283
Loyola University Experience	284
Treatment Protocol	284
Results	284
Discussion	285
Potential Adverse Effects	286
Commentary—Melvin D. Cheitlin, M.D.	290
 17 Should the Patient with Suspected Acute Dissection of the Aorta Have MRI, CAT Scan, or Aortography as the Definitive Study?	 293
<i>Mark W. Anderson, M.D., and Charles B. Higgins, M.D.</i>	
Clinical Features	293
Imaging	294
Plain Film	294
Angiography	294
Computed Tomography	294
Echocardiography	298
Magnetic Resonance Imaging	299
Commentary—Melvin D. Cheitlin, M.D.	305
 INDEX	 307

PART 1

Coronary Heart Disease

PART I

Coronary Heart Disease